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A
 
BSTRACT
Background:
 
The efficacy of montelukast, a specific
cysteinyl leukotriene receptor antagonist, in preventing
recurrent asthma attacks was evaluated for post-
emergency management of acute asthma exacerbation.
 
Methods:
 
Twenty-two patients with a history of chronic
asthma whose symptoms were responsive to an
inhaled 
 
β
 
-adrenergic receptor agonist in an emer-
gency room setting, were randomized into two groups,
those with and those without montelukast (
 
n
 
 = 11 for
each group). Patients in the montelukast group
received an oral dose of 10 mg montelukast before
leaving the emergency room following rescue treat-
ment with an inhaled 
 
β
 
-adrenergic receptor agonist.
Patients in both groups were instructed to use an
inhaled 
 
β
 
-adrenergic receptor agonist for shortness of
breath or dyspnea in post-emergency management.
Additional 
 
β
 
-adrenergic receptor agonist use, subjec-
tive asthma symptoms, sleep impairment, additional
emergency visits and/or hospitalization were moni-
tored for 24 hours following the emergency room visit.
 
Results:
 
In the montelukast group, the need for a
rescue 
 
β
 
-adrenergic receptor agonist was significantly
decreased; 54.5% of patients in the montelukast group
required use of 
 
β
 
-adrenergic receptor agonist com-
pared with 100% in the non-montelukast group
(
 
P
 
 < 0.05). The average number of uses of a 
 
β
 
-
adrenergic receptor agonist was 2.67 
 
±
 
 3.58 times/
24 h in the montelukast group compared with
11.95 
 
±
 
 3.60 times/24 h in the non-montelukast
group (
 
P
 
 < 0.01). The average subjective asthma
symptom scores were significantly decreased in the
montelukast group, whereas no score change
occurred in the non-montelukast group. The sleep
impairment score was significantly lower in the monte-
lukast group compared with that in the non-
montelukast group (
 
P
 
 < 0.05). No patients in either
group had an emergency visit or hospitalization during
this period.
 
Conclusions:
 
The results demonstrate that monte-
lukast can prevent recurrent asthma exacerbations in
the home environment.
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β
 
2
 
-adrenergic receptor agonist, asthma
exacerbation, leukotriene receptor antagonist, monte-
lukast.
 
I
 
NTRODUCTION
 
In the management of asthma, the choice of drugs for
controlling recurrent acute asthma exacerbations, espe-
cially in the home environment, is important for patients
who have been released from hospital emergency care.
Continuous use of inhaled 
 
β
 
-adrenergic receptor ago-
nists in combination with systemic administration of
corticosteroids was recommended by the Global Initia-
tive for Asthma (GINA) guidelines (2002) as a treatment
for such conditions.
 
1
 
 However, systemic corticosteroids
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are slow acting and it takes 4–6 h for the clinical effects
of systemic corticosteroids to be manifested on acute
asthma exacerbation.
 
2
 
 In contrast, 
 
β
 
-adrenergic receptor
agonists are rapid and short acting, but they are effective
only in a portion of acute asthmatic patients.
 
3
 
 Thus, no
adequate progress has been made in the drug treatment
of acute asthma over the past 20 years,
 
4
 
 despite the fact
that the prevalence of emergency room visits following
an acute asthma attack has increased substantially.
Leukotriene (LT) receptor antagonists have emerged
as an important treatment for the long-term control
of chronic asthma.
 
5,6
 
 Evidence suggesting the clinical
benefit of LT receptor antagonists has accumulated in
acute asthmatic patients and their effectiveness is due to
the rapid onset of their bronchodialating effect.
 
7,8
 
 In the
present study, we examine the effect of montelukast, a LT
receptor antagonist, in the prevention of the recurrence
of acute asthma exacerbations in patients who have been
released after receiving rescue 
 
β
 
-adrenergic receptor
agonist treatment in an emergency room.
 
M
 
ETHODS
 
The subjects of the present study were 22 patients with
a 1 year or more history of asthma, whose mild to
moderate asthma exacerbations responded to the use of
inhaled 
 
β
 
-adrenergic agonists in an emergency care
visit. None of the study subjects had received systemic
corticosteroid therapy. An improvement of acute asthma
exacerbation with 
 
β
 
-adrenergic receptor agonists was
measured in terms of physical parameters, such as
auscultatory findings, heart rate and respiratory rate,
and symptoms of respiratory distress lasting for 1 h or
more in an emergency room visit.
Subjects were randomized into two groups: those
patient given montelukast and those not (
 
n
 
 = 11 for each
group). While still in the emergency room, patients in the
montelukast group received a single oral dose of 10 mg
montelukast just after rescue treatment with an inhaled
 
β
 
-adrenergic receptor agonist and were prescribed
montelukast for 3 days. Patients in the non-montelukast
group received no medication other than the initial
rescue treatment. The study subjects excluded patients
who needed further intensive treatment, such as in-
patient care, those who had previously used LT receptor
antagonists and those who had been using nebulized
 
β
 
-adrenergic receptor agonists in the home environment.
As post-emergency room management, both groups
were instructed to use inhaled 
 
β
 
-adrenergic receptor
agonists with a metered-dose inhaler for recurrent
asthma exacerbations as needed and to take a second
dose of the 
 
β
 
-adrenergic receptor agonist if the recurrent
attack was not relieved within 30 min of the first dose.
If the attack persisted after the second dose, patients
were instructed to return to the emergency room.
The primary end-point for evaluating recurrence of
asthma exacerbation in the home environment was the
frequency of inhaled 
 
β
 
-adrenergic receptor agonist use,
which was monitored in the 24 h period between release
from the emergency care visit and the out-patient visit of
the following day, and was expressed as the calculated
number of 
 
β
 
-adrenergic receptor agonist uses per 24 h.
The secondary end-points were subjective asthma
symptom scores, nocturnal sleep impairment scores and
number of emergency visits or hospitalizations. The
scores of subjective asthma symptoms and nocturnal
sleep impairment for the worst asthmatic attack before
and after the emergency visit were determined according
to the criteria of the Japanese Society of Allergology
(Table 1) in patient interviews.
 
9
 
Data are expressed as the mean 
 
±
 
 SD. Differences
between groups were analyzed by Student’s 
 
t
 
-tests and
Fisher’s exact test at a two-tailed significance of 5%.
 
R
 
ESULTS
 
Baseline patient characteristics of both groups are
shown in Table 2. The treatment programs for asthma
before the emergency care visit were similar in the two
groups. Home management of chronic asthma in all
patients was not adequately sustained, even with
clinic visits. Both the average severity of asthma in the
home environment measured with subjective asthma
symptom scores prior to the emergency visit and mean
room air 
 
S
 
p
 
O
 
2
 
 at the emergency visit were similar in
both groups.
 
Frequency of inhaled 
 
β
 
-adrenergic receptor 
agonist use
 
Subsequent to the emergency visit, all te patients in the
non-montelukast group needed inhaled 
 
β
 
-adrenergic
receptor agonists, whereas only six patients (54.5%) in
the montelukast group did (
 
P
 
 < 0.05). The frequency of
 
β
 
-adrenergic receptor agonist use was significantly lower
in the montelukast group compared with the non-
montelukast group (2.67 
 
±
 
 3.58 and 11.95 
 
±
 
 3.60
times/24 h, respectively; 
 
P
 
 < 0.01; Fig. 1).
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Subjective asthma symptom score
Changes in the average subjective asthma symptom
score at the worst asthma attack before and after the
emergency care visit were from 3.05 ± 1.23 to
2.64 ± 1.55 in the group without montelukast and from
3.14 ± 1.67 to 0.82 ± 0.78 in the montelukast group
(Fig. 2). The decrease was significant in the montelukast
group (P < 0.01), but not in the non-montelukast group
(P = 0.51).
When the percentage change from baseline in the
score of individual patients was calculated and then aver-
aged, the average percentage reduction from baseline
was significantly higher in the montelukast group than
in the non-montelukast group (59.8 
 
±
 
 39.6 and 6.1 
 
±
 
48.5%, respectively; 
 
P
 
 < 0.05).
Table 1 Criteria of asthma symptoms and nocturnal sleep impairment scores prepared by the Japanese Society of Allergology9
Score (points)
Asthma symptom scores
Severe asthma exacerbation 9
Moderate asthma exacerbation 6
Mild asthma exacerbation 3
Wheeze 1
Severe cough 0.5
Mild cough 0.5
None 0
Nocturnal sleep impairment scores
Not possible because of respiratory distress 9
Difficult because of respiratory distress 6
Fairly possible despite respiratory distress 3
Peaceful 0
Table 2 Characteristics of study subjects
Characteristics Non-montelukast group 
(
 
n
 
 = 11)
Montelukast group 
(
 
n
 
 = 11)
Mean (
 
± 
 
SD) ages (years) 41.2 
 
± 
 
15.5 40.9 
 
± 
 
16.9
Sex (no. males/females) 5/6 4/7
Mean (±SD) duration of asthma (years) 12.6 ± 15.3 9.8 ± 10.9
Smoking (no. smokers/non-smokers) 4/7 4/7
Severity (no. mild/moderate/severe) 7/4/0 6/5/0
Mean (
 
± 
 
SD) attack score before emergency visit (points) 3.1 
 
± 
 
1.2 3.1 
 
± 
 
1.7
Treatment programs for asthma before the emergency visit (
 
n
 
)
No regular treatment program 5 5
Oral 
 
β
 
-adrenergic receptor agonists as needed 1 1
Inhaled 
 
β
 
-adrenergic receptor agonists as needed 4 3
Irregular inhaled corticosteroids 1 2
Fig. 1 Frequency of inhaled β-adrenergic receptor agonist
use, monitored in the 24 h period between the release from
emergency care visit and the out-patient visit of the following
day, expressed as the calculated number of 
 
β
 
-adrenergic recep-
tor agonist uses per 24 h. Values are the mean 
 
± 
 
SD for 
 
n
 
 = 11
subjects per group.
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Nocturnal sleep impairment score
The nocturnal sleep impairment score after an emer-
gency care visit was significantly lower (2.72 ± 2.10) in
the montelukast group compared with the non-montelukast
group (5.45 ± 1.23), suggesting that nocturnal sleep
was significantly improved with montelukast (P < 0.01;
Fig. 3).
Number of emergency return visits and/or 
hospitalizations
No patient in either group returned to the emergency
room or was hospitalized subsequent to the emergency
care visit.
DISCUSSION
In the present clinical study in emergency room asth-
matic patients whose acute exacerbation responded to
rescue β-adrenergic receptor agonists, a single oral
dose of montelukast given before leaving the emergency
room significantly reduced the subsequent use of
β-adrenergic receptor agonists, as well as scores of
subjective asthma symptoms and sleep disturbance.
The results demonstrate the beneficial effect of monte-
lukast in the home management of recurrent asthma
exacerbations.
The pathophysiology of asthma has become increas-
ingly more understood in recent years. The drugs of first
choice for the treatment of an asthma attack in the
emergency room have been short-acting β-adrenergic
receptor agonists, according to the treatment guidelines
for acute asthma.1 When patients are relieved from an
acute asthma attack by treatment, and the ameliorating
effect continues, they are allowed to go home after an
adequate home management program for recurrent
attacks is given. In the GINA guidelines, the continual use
of inhaled β-adrenergic receptor agonists in combination
with systemic corticosteroids has been recommended for
such post-emergency management of asthma exacer-
bations.1 However, this treatment is inadequate as the
management method for the following reasons: (i)
approximately one-third of patients in an emergency
setting poorly respond to short-acting β-adrenergic
receptor agonists;3 and (ii) corticosteroids have a delayed
clinical effect, resulting in 4–6 h or even longer before
patients have relief.2 Furthermore, the use of systemic
corticosteroids in patients with acute asthma does not
improve pulmonary function within 6 h of their adminis-
tration nor do systemic corticosteroids reduce hospitaliza-
tions of such patients, as revealed in a recent meta-
analysis.10 Although the alternative combination of an
inhaled anticholinergic agent and an inhaled β-
adrenergic receptor agonist produced a better broncho-
dilating effect and reduced the number of hospitalizations
in patients with acute asthma,11 anticholinergic agents
themselves have been ineffective in the treatment of
Fig. 2 Changes in the average subjective asthma symptom
score at the worst asthma attack before () and after () the
emergency care visit. The scores of subjective asthma symptoms
were taken according to the criteria of the Japanese Society of
Allergology9 in patient interviews. Values are the mean ± SD for
n = 11 subjects per group.
Fig. 3 Nocturnal sleep impairment scores after an emergency
care visit. The scores of nocturnal sleep impairment were taken
according to the criteria of the Japanese Society of Allergology9
in patient interviews. Values are the mean ± SD for n = 11
subjects per group.
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β-adrenergic receptor agonist-resistant asthma exacer-
bations and, in the study of McFadden et al., the pres-
ence of an anticholinergic agent in the β-adrenergic
receptor agonist regimen did not influence the treatment
effect.12 The effects of intravenous injections of methylx-
anthine,13 magnesium14 and helium–oxygen therapy15
have been investigated for the same clinical aspect, but
there has been no conclusive consensus reached yet
regarding their beneficial effects in the treatment of acute
asthma. Thus, finding a drug that has fast action and
a sustained effect for preventing recurrent asthma
exacerbations is one of the important goals in the post-
emergency management of acute asthma.
Cysteinyl LT are implicated in acute asthma, as evi-
denced by the elevated cysteinyl LT concentration in urine
and induced sputum during an acute asthma attack.16,17
The metabolites of arachidonic acid, produced by
5-lipoxygenase, mediate not only inflammatory cell
chemotaxis of eosinophils and microvascular perme-
ability, but also bronchial smooth muscle constriction
and proliferation.18,19
Leukotriene receptor antagonists are considered effec-
tive drugs for the long-term control of chronic asthma
according to the GINA guidelines.1 Dockhorn et al.
demonstrated that both oral and intravenous montelukast
improved respiratory function in patients with chronic
asthma.20 The improvement in forced expiratory volume
in 1 s (FEV1) is much greater at 15 min after intravenous
administration and the effect continued for 24 h with a
single oral or intravenous dose of montelukast, suggest-
ing the relatively fast and sustained bronchodilating effect
of LT receptor antagonists. The effect of an LT receptor
antagonist in the prevention of acute asthma was also
indicated in a study in which administration of the drug
significantly inhibited airway constriction in response to
exercise,21 the inhalation of cold air22 or allergens23 in
patients with bronchial asthma. Clinical data for the use
of LT receptor antagonists in acute asthmatic patients
continue to accumulate. Camargo et al. compared the
effect of standard therapy (placebo group) with that of a
combination of standard therapy and intravenous monte-
lukast (montelukast group) in patients with acute asthma
who did not respond to an inhaled β-adrenergic receptor
agonist.7 Montelukast improved FEV1 over 20 min after
administration. The mean FEV1 increased significantly
from prerandomization baseline and the use of systemic
corticosteroids or β-adrenergic receptor agonists was
significantly less in patients in the montelukast group
compared with the placebo group. In a study of acute
asthmatic patients, peak respiratory flow increased more
in the group treated with a combination of the systemic
corticosteroid and oral montelukast compared with
systemic corticosteroid alone, although the difference
between the two groups was not significant.8 Leukotriene
receptor antagonists may be more effective in the
management of acute asthma rather than in the long-
term control of chronic asthma because the cysteinyl LT
production pathway is more active in acute asthma than
in the chronic form of the condition.16,17 However, there is
not enough evidence that LT receptor antagonists are
more effective as relievers of acute asthma than as con-
trollers of chronic asthma; thus, further investigation of
the significance of inhibiting cysteinyl LT activity during
asthma exacerbations is needed.
Although none of the subjects in the present study
sustained home management of chronic asthma ade-
quately, all subjects were responded to an inhaled
β-adrenergic receptor agonist in emergency care. How-
ever, the effect of the β-adrenergic receptor agonist was
transient, as evidenced by the need for additional doses
of the inhaled β-adrenergic receptor agonist for recurrent
exacerbation in both groups. Montelukast reduced the
use of the β-arenergic receptor agonist, subjective
asthma symptom scores and nocturnal sleep impairment
scores, suggesting the effectiveness of LT receptor antag-
onists in the prevention of recurrent asthma attacks in
patients with β-adrenergic receptor agonist-responsive
acute asthma whose chronic asthma management is not
adequately sustained. In fact, approximately half the
patients in the montelukast group needed to use a
β-adrenergic receptor agonist to some extent, but only
one of them needed to use it as often as the patients in
the non-montelukast group. In many previous studies, LT
receptor antagonists have been shown to possess several
anti-asthmatic effects, such as broncodilation and anti-
inflammatory effects. The rapid onset of action obtained
in the present clinical study suggests that the primary
mechanism of action of LT receptor antagonists in the
management of acute asthma is one of bronchodilation.
Although the impact of LT receptor antagonists on res-
piratory function with time during asthma exacerbations
was not investigated in the present study, this information
is needed to clarify the precise mechanism of action of LT
receptor antagonists.
There was a population of asthmatic patients who
were responsive to LT receptor antagonists and one that
was not: responders and non-responders found in the
study of the long-term control of chronic asthma.24–26
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Involvement of variants of the LTC4 synthase gene and the
5-lipoxygenase gene in responsiveness to LT receptor
antagonists has been suggested in some studies.24–26
However, Camargo et al. reported that the broncho-
dialating effect of montelukast on acute asthma was
observed in the majority of patients and their results did
not confirm the obvious existence of responders or non-
responders.7
The results of the present study demonstrate the bene-
ficial effect of montelukast in the management of mild
asthma exacerbations without the need for the admin-
istration of systemic corticosteroids. However, further
investigation is needed to elucidate the role and impor-
tance of cysteinyl LT in the inflammation and constriction
of the pulmonary pathway in acute asthma and the signif-
icance of inhibiting cysteinyl LT activity in acute asthma.
Large-scale studies are needed to evaluate the thera-
peutic efficacy and usefulness of LT receptor antagonists
in patients with acute asthma, including comparisons
with anticholinergic agents and long-acting β-adrenergic
receptor agonists. In addition, the aim of the present clin-
ical study was not to compare the effectiveness directly
between established systemic corticosteroids therapy and
LT receptor antagonists in the management of asthma
exacerbations. Either a comparative study with systemic
corticosteroid therapy or an investigation of the add-on
effect of LT receptor antagonists to systemic corticosteroid
therapy is needed to prove the clinical usefulness of
LT receptor antagonists in the management of acute
asthma.
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